BEAM: BEAM-301: 2/3 patients at 40 mg reached 15 hours fasting and stopped cornstarch

What happened

BEAM-301 showed dose-dependent gains in fasting tolerance, with 2/3 patients at 40 mg reaching the 15-hour limit and eliminating cornstarch. Enrollment is underway at 60 mg, and FDA discussions are planned on a potential approval path.

Confirmed

Global impact / market context

Reaching 15 hours of fasting without cornstarch, a starch used to prevent low blood sugar, suggests the treatment may reduce daily diet management. If later testing confirms this, simpler routines could support adoption and strengthen the case for Beam Therapeutics' pipeline.

Analyst inference

The results are early-stage and cover few patients, so they do not prove the drug works. Enrollment at 60 mg and planned FDA talks signal a push toward a regulatory path, but approval timing and whether larger studies replicate these gains remain unknown.

Analyst inference

What to watch

1. Enrollment at the 60 mg dose is underway, which will test whether higher dosing produces further gains in fasting tolerance and whether side effects remain manageable. Confirmed
2. FDA discussions are planned on a potential approval path; watch for details on required trial size, endpoints and timelines, since these shape future spending and regulatory risk. Proposed
3. Watch whether the 15-hour fasting result and cornstarch elimination hold in more patients, because weak replication would undercut the commercial case and could weigh on investor positioning in BEAM. Analyst inference

Evidence

• Original source link unavailable